Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Ibandronate 2.5 mg	400
Overall Study	STARTED	Ibandronate 50/50 mg	401
Overall Study	STARTED	Ibandronate 100 mg	400
Overall Study	STARTED	Ibandronate 150 mg	401
Overall Study	COMPLETED	Ibandronate 2.5 mg	325
Overall Study	COMPLETED	Ibandronate 50/50 mg	328
Overall Study	COMPLETED	Ibandronate 100 mg	316
Overall Study	COMPLETED	Ibandronate 150 mg	322
Overall Study	NOT COMPLETED	Ibandronate 2.5 mg	75
Overall Study	NOT COMPLETED	Ibandronate 50/50 mg	73
Overall Study	NOT COMPLETED	Ibandronate 100 mg	84
Overall Study	NOT COMPLETED	Ibandronate 150 mg	79

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00048061/flow